AB-101-05

A Phase 2a, open-label study to evaluate the safety and efficacy of AlloNK® (allogeneic NK-cell therapy derived from umbilical cord blood) in combination with rituximab in relapses of B-cell-dependent rheumatic diseases

Condition studied : Systemic sclerosis, Rheumatoid arthritis, Idiopathic inflammatory myopathies
Treatment : Combined administration of AlloNK® and Rituximab
Sponsor : Artiva
Principal Investigator : Pr. Christian Jorgensen
: NCT 06991114, EU CT 2025-520461-41-00
Investigator
Pr. Christian Jorgensen
Director
Rechercher sur le site